Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

NCT01026376 is registered in ClinicalTrials.gov with Janssen-Cilag Farmaceutica Ltda. as lead sponsor.

NCT NCT01026376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Lead sponsor
Janssen-Cilag Farmaceutica Ltda.
Phase
Expanded access
Overall status
No longer available
Start date
June 30, 2008
Completion date
November 30, 2011
Enrollment
Not reported
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes